StonvexLoading…
StonvexStonvexStonvexCore line items from SANG's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-06-30 | Annual 2024 2024-06-30 | Annual 2023 2023-06-30 | Annual 2022 2022-06-30 |
|---|---|---|---|---|
Revenue | $236.69M | $247.28M | $252.53M | $224.35M |
Operating Income | $-6.34M | $-9.50M | $-31.96M | $-104.39M |
Net Income | $-5.01M | $-8.66M | $-29.03M | $-110.78M |
EPS (Diluted) | $-0.15 | $-0.26 | $-0.88 | $-3.52 |
Total Assets | $346.55M | $400.64M | $443.02M | $498.53M |
Total Liabilities | $92.35M | $140.91M | $176.90M | $204.72M |
Cash & Equivalents | $13.49M | $16.23M | $11.16M | $12.70M |
Free Cash Flow OCF − CapEx | $39.40M | $40.12M | $22.47M | $19.19M |
Shares Outstanding | 33.26M | 33.34M | 33.04M | 21.44M |